[137] demonstrated that the nanobody‐based CD30‐CD5‐CAR‐T cells exhibited superior anti‐tumor effects against T cell lymphoma (TCL) in both in vivo and in vitro experiments, suggesting that nanobody‐based CAR‐T cells could dramatically improve their anti‐tumor efficiency compared with conventional scFv‐derived CAR‐T cells. Here, CD5 is linked to neoplasm.